The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products

Pharmacology and Therapeutics

Volumn 120, Issue 1, 2008, Pages 71-80

  Woodward, D F ^a   Carling, R W C ^b   Cornell, C L ^b   Fliri, H G ^b   Martos, J L ^b   Pettit, S N ^b   Liang, Y ^a   Wang, J W ^a  

^a ALLERGAN INC   (United States)

^b Selcia Ltd   (United Kingdom)

Author keywords

2 arachidonyl glycerol; Anandamide; Bimatoprost; Cyclo oxygenase 2; Prostaglandin ethanolamide; Prostaglandin glyceryl ester

Indexed keywords

AGN 204396; AGN 204397; AGN 211334; AGN 211335; AGN 211336; ANANDAMIDE; BIMATOPROST; CYCLOOXYGENASE 2; ENDOCANNABINOID; ETHANOLAMIDE; GLYCEROL DERIVATIVE; PROSTAGLANDIN; PROSTAMIDE; PROSTAMIDE E2; PROSTANOID RECEPTOR; THROMBOXANE; UNCLASSIFIED DRUG;

ARACHIDONIC ACID METABOLISM; CORNEA; DRUG POTENCY; DRUG SYNTHESIS; ELECTROCHEMICAL ANALYSIS; GLAUCOMA; HUMAN; INTRAOCULAR HYPOTENSION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; REVIEW; SCLERA;

ANIMALS; ARACHIDONIC ACIDS; CYCLOOXYGENASE 2; ENDOCANNABINOIDS; GLAUCOMA; HUMANS; POLYUNSATURATED ALKAMIDES; PROSTAGLANDIN ANTAGONISTS;

EID: 51649093696     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.08.001     Document Type: Review

References (80)

1. Alm A., Schoenfelder J., and McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol 122 (2004) 957-965
2. Arcieri E.S., Santana A., Rocha F.N., Guapo G.L., and Costa V.P. Blood-aqueous barrier changes after the use of the prostaglandin analogues in patients with pseudophakia and aphakia: a 6 month randomized trial. Arch Ophthalmol 123 (2005) 186-192
3. Ayyala R.S., Cruz D.A., Margo C.E., Harman L.E., Pautler S.E., Misch D.M., Mines J.A., and Richards D.W. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol 126 (1998) 602-604
4. 2 cannabinoid receptors in rat brain and human tonsils. Adv Exp Med Biol 469 (1999) 527-533
5. Bito L.Z. Species differences in the responses of the eye to irritation and trauma; a hypothesis of divergence in ocular defense mechanisms, and the choice of experimental animals for eye research. Exp Eye Res 39 (1984) 807-829
6. 2α-1-isopropyl ester. Exp Eye Res 44 (1987) 217-226
7. Brubaker R.F., Schoff E.O., Nau C.B., Carpenter S.P., Chen K., and Van Den Burgh A.M. Effect of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 131 (2001) 19-24
8. Burstein S.H., Rossetti R.G., Yagen B., and Zurier R.B. Oxidative metabolism of anandamide. PGs Other Lipid Med 61 (2000) 29-41
9. Callanan D., Fellman R.L., and Savage J.A. Latanoprost-associated cystoid macular edema. Am J Ophthalmol 126 (1998) 134-135
10. Chen J., Senior J., Marshall K., Abbas F., Dinh H., Dinh T., et al. Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles. Br J Pharmcol 144 (2005) 493-501
11. 2α. Br J Ophthalmol 78 (1994) 560-567
12. Christiansen G.A., Nau C.B., McLaren J.W., and Johnson D.H. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmol 111 (2004) 1658-1662
13. Cohen J.S., Gross R.L., Cheetham J.K., VanDenburgh A.M., Bernstein P., and Whitcup S.M. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol 49 (2004) S45-S52
14. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., and Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (1996) 83-87
15. De Petrocellis L., Cascio M.G., and Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141 (2004) 765-774
16. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Nat Acad Sci U S A 99 (2002) 10819-10824
17. Dubiner H., Cooke D., Dirks M., Stewart W., Vandenburg A.M., and Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure. Surv Opthalmol 45 (2001) S353-S360
18. Eakins K.E. Prostaglandin and non-prostaglandin mediated breakdown of the blood-aqueous barrier. Exp Eye Res 4 (1977) 483-498
19. Fechtner R.D., Khouri A.S., Zimmerman T.J., Bullock J., Feldman R., Kulkarni P., Michael A.J., Realini T., and Warwar R. Anterior uveitis associated with latanoprost. Am J Ophthalmol 126 (1998) 37-41
20. Gagliuso D.J., Wang R.F., Mittag T.W., and Podos S.M. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes. Arch Ophthalmol 122 (2004) 1342-1347
21. Gandolfi S.A., and Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma and ocular hypertension who are nonresponders to latanoprost. Ophthalmol 110 (2003) 609-614
22. Glass M., Hong J., Sato T.A., and Mitchell M.D. Misidentification of prostamides as prostaglandins. J Lipid Res 46 (2005) 1364-1368
23. Hampson A.J., Hill W.A., Zan-Philips M., Makriyannis A., Leung E., Eglen R.M., and Bormheim L.M. Anandamide hydroxylation by brain lipoxyenase: metabolite structures and potencies at the cannabinoid receptor. Biochem Biophys Acta 1259 (1995) 173-179
24. Higginbotham E.J., Schuman J.S., Goldberg I., Gross R.L., Vandenburgh A., Chen K., and Whitcup S.M. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 120 (2002) 1286-1293
25. Hollo G. The side effects of the prostaglandin analogues. Expert Opin Drug Safety 6 (2007) 45-52
26. 2 glycerol ester, an endogenous COX-2 metabolite of arachidonylglycerol, induces hyperalgesia and modulates NFκB activity. Br J Pharmacol 153 (2008) 1538-1549
27. Karlsson M., Contreras J.A., Hellman U., Tornquist H., and Holm C. cDNA cloning, tissue distribution, and identification of the catalytic triad of haloperoxidases. J Biol Chem 272 (1997) 27218-27223
28. Kitazawa Y. An open-label multicenter study on the efficacy and safety of topical use of latanoprost for 156 weeks. Jap J Clin Ophthalmol 60 (2006) 2047-2054
29. Koda N., Tsutsui Y., Niwa H., Ito S., Woodward D.F., and Watanabe K. Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of bimatoprost as a potent inhibitor of the enzyme. New enzyme method by LC/GSI/MS. Arch Biochem Biophys 424 (2003) 128-136
30. 2 by Prostaglandin F Synthase. (PGFS): Crystal structure of PGFS containing bimatoprost. Biochem 45 (2006) 1987-1996
31. Kozak K.R., Crews B.C., Morrow J.D., Wang L.H., Ma Y.H., Weinander R., and Jakobsson PJ Marnett L.J. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277 (2002) 44877-44885
32. Kozak K.R., Crews B.C., Ray J.L., Tai H.H., Morrow J.D., and Marnett L.J. Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. J Biol Chem 278 (2001) 36993-36998
33. Kozak K.R., Rowlinson S.W., and Marnett J.L. Oxygenation of the endocannabinoid 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem 275 (2000) 33744-33749
34. Laibovitz R.A., Van Den Burgh A.M., Felix C., David R., Batoosingh A., Rosenthal A., and Cheetham J. Comparison of the ocular hypotensive lipid AGN 192024 with timolol. Dosing, efficacy and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol 199 (2001) 994-1060
35. 2 agonist) on Cyr 61 and CTGF gene expression. J Biol Chem 278 (2003) 27267-27277
36. 2 receptor activated Nur 77 gene transcription. Br J Pharmacol 142 (2004) 737-748
37. Lichtman A.H., Hawkins A.G., Griffin G., and Cravatt B.F. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther 302 (2002) 73-79
38. Maddox Y.T., Ramwell P.W., Shiner C.S., and Corey E.J. Amide and 1-amino derivatives of prostaglandins as prostaglandin antagonists. Nature 273 (1978) 549-552
39. Matias I., Chen J., De Petrocellis L., Bisogno T., Ligresti A., Fezza F., et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther 309 (2004) 745-757
40. Miyake K., Ota I., Maekubo K., Ichihashi S., and Miyaki S. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperotive pseudophakias. Arch Ophthalmol 117 (1999) 34-40
41. Modschiedler K., Von den Driesch P., and Paus R. Hyperpigmetosis hypertrichosis of the eyelids after use of bimatoprost eye drops. J Dtsch Dermatol Ges 3 (2005) 267-277
42. Moroi S.E., Gottfredsdottir M.S., Schteingart M.T., Elner S.G., Lee C.M., Schertzer R.M., Abrams G.W., and Johnson M.W. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmol 106 (1999) 1024-1029
43. Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoid receptors: structure, properties, and functions. Pharmacol Rev 79 (1999) 1193-1226
44. Neufeld A.H., and Sears M.L. Prostaglandin and eye. PGs 4 (1973) 157-175
45. 2 mobilizes calcium and activates signal transduction in RAW 264.7 cells. Proc Nat Acad Sci 101 (2004) 1840-1845
46. Noecker R.S., Dirks M.S., Choplin N.T., Bernstein P., Batoosongh A.L., and Whitcup S.M. A six-month randomized clinical trail comparing the intraocular pressure lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 135 (2003) 55-63
47. Parrish R.K., et al., for the XLT Study Group. A comparison of latanoprost, bimatoprost, and travaprost in patients with elevated intraocular pressure: a 12-week randomized, masked evaluation multicenter study. Am J Ophthalmol 135 (2003) 688-703
48. Regan J.W., Bailey T.J., Pepperl D.J., Pierce K.L., Bogardus A.M., Donello J.E., et al. Cloning of a novel human prostaglandin receptors with characteristics of the pharmacologically defined EP2 subtype. Mol Pharmacol 46 (1994) 213-220
49. 2α prostaglandin glyceryl esters in RAW 264.7 and H1819 cells. Proceedings of the 10th International Conference on Bioactive Lipids in Cancer, Inflammation, and Related Diseases (2007) 191
50. Richter M., Krauss A.H.-P., Woodward D.F., and Lütjen-Drecoll E. Morphological changes in the anterior eye segment after long term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci 44 (2003) 4419-4426
51. Rockwell C.E., and Kaminski N.E. A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J Pharmacol Exp Ther 34 (2004) 683-690
52. 2 ethanolamide. J Pharmacol Exp Ther 301 (2002) 900-907
53. Rouzer C.A., and Marnett L.J. Glyceryl prostaglandin synthesis by resident peritoneal macrophages in response to a zymosan stimulus. J Biol Chem 280 (2005) 26690-26700
54. Rouzer C.A., Ghebreselaise K., and Marnett L.J. Chemical stability of 2-arachidonylgycerol under biological conditions. Chem Phys Lipids 119 (2002) 69-82
55. Schaaf T.K. Prostaglandin structure-activity relationships. In: Gordon M., Francis J., Whitfield G., Hess H.J., Shen T.Y., and Counsell R. (Eds). Annual Reports in Medicinal Chemistry (1976), Academic Press, New York 80-88
56. Schaaf T.K., and Hess H.J. Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogs. J Med Chem 22 (1979) 1340-1346
57. 2+ mobilization studies. PGs Lts & Essential Fatty Acids 68 (2003) 27-33
58. Sherwood M., and Brandt J. Six-month comparison of bimatoprost once-daily and twice daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 45 (2001) S361-S368
59. 2α selectively stimulate intracellular calcium signaling in different cat iris sphincter cells. Exp Eye Res 80 (2005) 135-145
60. 2α-isopropyl ester to latanoprost: A review of the development of Xalatan. Invest Ophthalmol Vis Sci 42 (2001) 1134-1145
61. Tosti A., Pazzaglia M., Voudouris S., and Tosti G. Hypertrichosis of the eyelashes caused by bimatoprost. J Am Acad Dermatol 51 (2004) S149-S150
62. Ueda N., Yamamoto K., Yamamoto S., Tokunaga T., Shirakawa E., Shinaki H., et al. Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. Biochem Biophys Acta 1254 (1995) 127-134
63. Wan Z., Woodward D.F., Cornell C., Fliri H., Martos J., Pettit S., et al. Bimatoprost prostamide activity, and conventional drainage. Invest Ophthalmol Vis Sci 48 (2007) 4105-4115
64. Wand M., and Gaudio A.R. Cystoid macular edema associated with ocular hypotensive lipids. Am J Ophthalmol 133 (2002) 403-405
65. Warwar R.E., Bullock J.D., and Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Ophthalmol 105 (1998) 263-268
66. Webb M.L., Liu E.C.K., Monschizadegan H., Hedberg A., Misra R.N., Goldenberg H., and Harris D.N. Binding and function of a potent new thromboxane receptor antagonist, BMS 180,291, in human platelets. J Pharmacol Exp Ther 264 (1993) 1387-1394
67. Weber A., Ni J., Ling K., H-J, Acheampong A., Tang-Liu D.D.S., Cravatt B.F., and Woodward D.F. Formation of prostaglandin 1-ethanolamides (prostamides) from anandamide in Fatty Acid Amide Hydrolose knockout (FAAH -/-) mice analyzed by high performance liquid chromatography with tandem mass spectrometry. J Lipid Res 45 (2004) 757-763
68. Williams R.D. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther 19 (2002) 275-281
69. Wei B.Q., Mikkelsen T.J., McKinney M.K., Lander E.S., and Cravatt B.F. A second fatty acid amide Hydrolase with variable distribution among placental mammals. J Biol Chem 281 (2006) 36569-36578
70. Woodward D.F., and Chen J. Fixed-combination and emerging glaucoma therapies. Expert Opin Emerging Drugs 12 (2007) 313-327
71. 2+ signals in Swiss 3T3 cells. Biochem Pharmacol 47 (1994) 1567-1574
72. 2α prodrugs in ocular tissues. Exp Eye Res 63 (1996) 411-423
73. 2α with a hydroxyl or methoxy substituent provides biologically unique compounds. Br J Pharmacol 130 (2000) 1933-1943
74. Woodward D.F., Krauss A.H.P., Chen J., Lai R.K., Spada C.S., Burk R.M., et al. The pharmacology of bimatoprost (Lumigan™). Surv Ophthalmol 45 (2001) S337-S345
75. Woodward D.F., Krauss A.H.P., Chen J., Liang Y., Li C., Protzman C.E., et al. Pharmacological characterizations of a novel antiglaucoma agent, bimatoprost (AGN 192024). J Pharmacol Exp Ther 305 (2003) 772-785
76. Woodward D.F., Krauss A.H.P., Wang J.W., Protzman C.E., Nieves A.L., Liang Y., et al. Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris. Br J Pharmacol 150 (2007) 342-352
77. Woodward D.F., Liang Y., and Krauss A.H.P. Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol 153 (2008) 410-419
78. Woodward D.F., Phelps R.L., Krauss A.H.P., Weber A., Short B., Chen J., et al. Bimatoprost: A novel anti-glaucoma agent. Cardiovasc Drug Rev 22 (2004) 103-120
79. 2. J Lipid Res 46 (2005) 2745-2751
80. 2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 272 (1997) 21181-21186